Subsequently, all interest charges are recorded as interest expense and other income and loss on our P&L. We are pleased with the operating leverage demonstrated through 2023, and we expect to continue trending towards cash flow breakeven driven by leverage over our fixed cost infrastructure and our focus on thoughtful operating expense management.
Nov 7, 2023 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-11-07 | transcript 39b8c9de-454b-4856-9a2a-966799155275 | chars 15383-15733 | segment 15
The increase was primarily due to compensation, marketing programs, and travel.
Nov 7, 2023 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-11-07 | transcript 39b8c9de-454b-4856-9a2a-966799155275 | chars 13466-13545 | segment 13
We expect to continue trending towards cash flow breakeven, driven by leverage over our fixed cost infrastructure and our focus on thoughtful operating expense management.
Aug 7, 2023 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-08-07 | transcript 336014fe-05a9-4e92-9cd7-3bb67248000e | chars 21435-21606 | segment 21
We anticipate spending $1.7 to $2.7 million to complete the APC facility, primarily in the second quarter. We also expect our operating cash flow to continue trending towards breakeven, driven by leverage over our fixed cost infrastructure and our focus on thoughtful operating expense management.
May 9, 2023 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2023-05-09 | transcript e37eca42-27f7-4eeb-8bda-3167c1bbb1bf | chars 15962-16259 | segment 15
We expect our operating cash to continue trending towards cash flow break-even, driven by revenue leverage on our fixed-cost infrastructure, along with our continued focus on thoughtful operating expense management.
Nov 8, 2022 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-11-08 | transcript 7c0d0e6f-cc72-47bc-8871-df1faf6c4b40 | chars 16365-16580 | segment 16
Total operating expense in the second quarter increased 7% to $36.1 million, compared to $33.6 million in the prior year. The increase in total operating expenses was primarily the result of an increased product development and clinical programs, as well as total compensation, including non-cast stock comp and travel costs.
Aug 3, 2022 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-08-03 | transcript 7c2c9db7-14cd-44c2-90dd-76e3b425e176 | chars 12720-13045 | segment 12
Sales and marketing expense in the second quarter increased 2% to $19.7 million compared to $19.3 million in the prior year. The increase was primarily due to increased sales travel.
Aug 3, 2022 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-08-03 | transcript 7c2c9db7-14cd-44c2-90dd-76e3b425e176 | chars 13046-13228 | segment 12
The decrease is primarily due to a reduction in employee compensation where decreases in incentive and stock compensation bonus and commissions were partially offset by increases in salaries. The net decrease in operating expense was partially offset by increases in professional and consulting fees, marketing programs and travel, and research and development projects.
Feb 22, 2022 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-02-22 | transcript 7e2d8acb-0da4-44ce-99f7-daf04966cf53 | chars 12522-12892 | segment 12
Sales and marketing expense in the fourth quarter decreased 11% to $17.7 million compared to $19.8 million in the prior year. The decrease is primarily related to lower employee compensation, partially offset by an increase in marketing programs and travel.
Feb 22, 2022 / CFO / receipt, needs a key / Pete Mariani, CFO | earnings call 2022-02-22 | transcript 7e2d8acb-0da4-44ce-99f7-daf04966cf53 | chars 12893-13150 | segment 12